



This is a repository copy of *De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/156679/>

Version: Published Version

Article:

Kirov, G., Pocklington, A.J., Holmans, P. et al. (27 more authors) (2012) De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. *Molecular Psychiatry*, 17 (2). pp. 142-153. ISSN 1359-4184

<https://doi.org/10.1038/mp.2011.154>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

IMMEDIATE COMMUNICATION

De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia

G Kirov¹, AJ Pocklington¹, P Holmans¹, D Ivanov¹, M Ikeda², D Ruderfer^{3,4,5}, J Moran⁵, K Chambert⁵, D Toncheva⁶, L Georgieva¹, D Grozeva¹, M Fjodorova¹, R Wollerton¹, E Rees¹, I Nikolov¹, LN van de Lagemaat⁷, À Bayés⁷, E Fernandez⁸, PI Olason⁹, Y Böttcher⁹, NH Komiyama⁷, MO Collins¹⁰, J Choudhary¹⁰, K Stefansson⁹, H Stefansson⁹, SGN Grant⁷, S Purcell^{3,4,5}, P Sklar^{3,4,5}, MC O'Donovan¹ and MJ Owen¹

¹Department of Psychological Medicine and Neurology, MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK; ²Department of Psychiatry, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan; ³Department of Psychiatry, Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; ⁴Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA; ⁵Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, USA; ⁶University Hospital Maichin Dom, Sofia, Bulgaria; ⁷Genes to Cognition Program, School of Molecular and Clinical Medicine, Edinburgh University, Edinburgh, UK; ⁸VIB Department of Molecular and Developmental Genetics, KU Leuven Medical School, Leuven, Belgium; ⁹deCODE Genetics, Reykjavík, Iceland and ¹⁰The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK

A small number of rare, recurrent genomic copy number variants (CNVs) are known to substantially increase susceptibility to schizophrenia. As a consequence of the low fecundity in people with schizophrenia and other neurodevelopmental phenotypes to which these CNVs contribute, CNVs with large effects on risk are likely to be rapidly removed from the population by natural selection. Accordingly, such CNVs must frequently occur as recurrent *de novo* mutations. In a sample of 662 schizophrenia proband–parent trios, we found that rare *de novo* CNV mutations were significantly more frequent in cases (5.1% all cases, 5.5% family history negative) compared with 2.2% among 2623 controls, confirming the involvement of *de novo* CNVs in the pathogenesis of schizophrenia. Eight *de novo* CNVs occurred at four known schizophrenia loci (3q29, 15q11.2, 15q13.3 and 16p11.2). *De novo* CNVs of known pathogenic significance in other genomic disorders were also observed, including deletion at the TAR (thrombocytopenia absent radius) region on 1q21.1 and duplication at the WBS (Williams–Beuren syndrome) region at 7q11.23. Multiple *de novos* spanned genes encoding members of the DLG (discs large) family of membrane-associated guanylate kinases (MAGUKs) that are components of the postsynaptic density (PSD). Two *de novos* also affected *EHMT1*, a histone methyl transferase known to directly regulate *DLG* family members. Using a systems biology approach and merging novel CNV and proteomics data sets, systematic analysis of synaptic protein complexes showed that, compared with control CNVs, case *de novos* were significantly enriched for the PSD proteome ($P=1.72 \times 10^{-6}$). This was largely explained by enrichment for members of the *N*-methyl-D-aspartate receptor (NMDAR) ($P=4.24 \times 10^{-6}$) and neuronal activity-regulated cytoskeleton-associated protein (ARC) ($P=3.78 \times 10^{-8}$) postsynaptic signalling complexes. In an analysis of 18 492 subjects (7907 cases and 10 585 controls), case CNVs were enriched for members of the NMDAR complex ($P=0.0015$) but not ARC ($P=0.14$). Our data indicate that defects in NMDAR postsynaptic signalling and, possibly, ARC complexes, which are known to be important in synaptic plasticity and cognition, play a significant role in the pathogenesis of schizophrenia.

Molecular Psychiatry (2012) 17, 142–153; doi:10.1038/mp.2011.154; published online 15 November 2011

Keywords: CNV; *de novo*; DLG; EHMT1; postsynaptic; schizophrenia

Correspondence: Dr G Kirov, PhD, MRCPsych or Professor MC O'Donovan, PhD, FRCPsych, Department of Psychological Medicine and Neurology, Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK. E-mail: kirov@cardiff.ac.uk or odonovanmc@cf.ac.uk
Received 27 July 2011; revised 28 September 2011; accepted 4 October 2011; published online 15 November 2011

Introduction

Genome-wide association studies have found strong evidence for association between schizophrenia and a number of genetic variants, both common and rare.¹ So far, the evidence for rare variants comes mainly

from the analysis of deletions and duplications of segments of DNA known as copy number variants (CNVs). Cumulatively, as a general class, large (>100 kb) rare (<1%) CNVs occur more frequently in those with schizophrenia^{2,3} than controls, and several individual CNV loci have been strongly implicated as risk factors for schizophrenia with high degrees of statistical confidence. These include deletions at 1q21.1, *NRXN1*, 3q29, 15q11.2, 15q13.3, 22q11.2 and duplications at *VIPR2*, 16p11.2, 16p13.1 and 15q11-q13.^{2,4–13} Pleiotropic effects are common, the same CNV often conferring risk for a range of neurodevelopmental phenotypes including autism, mental retardation, attention deficit hyperactivity disorder and epilepsy, although interestingly, and in contrast to the findings with common risk alleles, there is little evidence that schizophrenia-associated CNVs confer risk for bipolar disorder.¹⁴

All of the currently known risk CNVs are rare (control frequencies typically <0.001) and confer substantial effects on risk (odds ratios 3–30). The known risk CNVs occur in 2–3% of cases, but it is likely that many other risk CNV loci remain to be identified. Most schizophrenia-associated CNVs span multiple genes, limiting our ability to make strong inferences regarding pathogenesis. Important exceptions are deletions of *NRXN1*, encoding the presynaptic neuronal cell adhesion molecule neurexin 1,^{11,15} pointing to the importance of as yet unspecified abnormalities of synaptic function in the disorder. Also, obscuring mechanistic insights from the CNV data are that most reported CNVs occurring in cases are too rare to allow clear demonstration of association statistically. One way to circumvent this is to test whether particular functionally related groups or sets of genes are enriched among case CNVs, rather than trying to interpret the results from individual CNVs. A limitation of this approach is that the enrichment of CNVs seen in case–control studies is modest;² indeed, one large study has reported no overall excess of CNVs in cases at all.⁴ This implies that among sets of CNVs drawn from cases, only a small proportion can be expected to be true risk factors for the disorder. Nevertheless, gene-set enrichment studies have supported conclusions drawn from consideration of genes affected by individual CNVs in schizophrenia¹⁶ by observing enrichment in schizophrenia of genes involved in a range of brain functions, for example, those encoding products involved in nitric oxide signalling, synaptic long-term potentiation and glutamate receptor signalling,¹⁷ or genes in a broad category corresponding to the gene ontology (GO) category ‘synaptic transmission’.¹⁸ However, it has been noted that the early gene-set studies did not allow for important confounders, in particular the large size of genes implicated in brain function, and that the conclusions that can be drawn are consequently unclear.¹⁹

Schizophrenia is associated with reduced fecundity, ~40% that of the general population,²⁰ or even lower according to the largest population-based

study.²¹ It follows that schizophrenia-related mutations of large effect should be rare because of intense purifying selection, and those that occur in multiple unrelated individuals are likely to do so through independent *de novo* mutations.^{7,22–24} One study on *de novo* CNV mutation in schizophrenia²⁴ showed that the rate of *de novo* CNV mutation in probands with no family history was 8 times higher in cases than in controls. This marked elevation in the rate of *de novo* CNVs contrasts with the relatively modest elevation in the rate of CNVs seen in case–control studies,^{2,4} and suggests that sets of *de novos* might be more informative for gene-set enrichment analyses.

Here, we report the largest analysis of *de novo* CNVs in schizophrenia to date. Our aims were to identify novel CNVs that increase risk of schizophrenia and to illuminate aspects of the pathophysiology of the disorder through gene-set enrichment analyses informed by recently curated proteomics data sets of synaptic protein complexes.

Materials and methods

Samples

Bulgaria The sample for *de novo* CNV analysis comprised 662 Bulgarian parent–proband trios from 638 families. We did not exclude probands ($N=61$) with a history of psychosis in a parent as none of the risk CNVs identified to date are sufficiently penetrant to fully explain the disorder in carriers. All cases had been hospitalised and met DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-fourth edition) criteria for schizophrenia or schizoaffective disorder based upon SCAN (Schedules for Clinical Assessment in Neuropsychiatry) interview by psychiatrists, and review of case notes. Cases were recruited from general adult psychiatric services and were typical of those attending those services. Although they did not have formal IQ assessments, all attended mainstream schools from which people with known mental retardation were excluded. All participants provided informed consent. Further details concerning ascertainment and diagnostic practices are provided in the Supplementary Material. All DNA samples were derived from peripheral venous blood.

Icelandic control de novos deCODE Genetics provided data for 2623 complete parent–offspring trios from the Icelandic population.⁷ Probands known to be affected with neurodevelopmental/psychiatric disorders (schizophrenia, autism, attention deficit hyperactivity disorder, mental retardation and bipolar affective disorder) had been excluded.

Autism case and control de novos Data on *de novo* rates in autism cases and their unaffected siblings are directly taken from the recent large study of Sanders *et al.*²⁵ based upon the Illumina (San Diego, CA, USA) 1M high-density array.

Case-control data sets We used four large publicly available data sets to which we also had access to the raw data. (1) The International Schizophrenia Consortium (ISC),² which included 3391 cases and 3181 controls genotyped with Affymetrix 6.0 or 5.0 arrays (Affymetrix, Santa Clara, CA, USA). Note that 328 Bulgarian cases from that study are probands in our trios (although their parents were not genotyped for *de novo* calling in the ISC study). We excluded those subjects from the ISC data. The ISC also included 605 unrelated controls recruited by us in Bulgaria (details in ref. 2) and those publicly available data were included in the present study. (2) The Molecular Genetics of Schizophrenia (MGS) Consortium,⁴ which included 3192 cases and 3437 controls genotyped with Affymetrix 6.0 arrays. (3) A UK case-control study of 471 schizophrenia and 2792 controls genotyped using the Affymetrix (Affymetrix) GeneChip500K Mapping Array (see ref. 3 for details of the sample and CNV calling). (4) CNV data reported by Ikeda *et al.*²⁶ comprising a Japanese sample of 519 cases and 513 controls. Including the data from the current study on transmissions and non-transmissions to affected offspring, and excluding the 328 overlapping Bulgarian cases, the combined case-control data sets contain a total of 7907 independent cases and 10 585 controls.

Genotyping and CNV analysis

Bulgarian samples Full details are provided in the Supplementary Material (Sections 1–3). All participants were genotyped with Affymetrix 6.0 arrays (Affymetrix) at the Broad Institute of Harvard and Massachusetts Institute of Technology. As an initial screen, we used Genotyping Console 4.0 software (Affymetrix, Santa Clara, CA, USA) to call autosomal CNVs, restricting initial calls to ≥ 10 kb and ≥ 10 probes. We next excluded individuals with > 50 CNV calls, as these were outliers from the distribution, followed by CNV loci with a frequency $> 1\%$ in the whole sample. We then excluded putative CNVs < 15 kb, covered by < 15 probes, or where $> 50\%$ of their length overlapped low copy repeats. Calls compatible with a *de novo* were made if a proband CNV was not spanned $> 50\%$ of its length by a CNV in either parent. Proband who had large numbers of apparent *de novos* (> 10) were excluded. After this initial screen with relaxed criteria to capture as many potential *de novos* as possible, we measured probe Log2 ratios derived from PennCNV.²⁷ We then used a slight modification of the MeZOD algorithm¹² (Supplementary Section 3) to visualise outlier signals in probands potentially indicative of *de novos* (Figure 1). Again, we used relaxed criteria, only excluding clear false positives (Supplementary Section 3). For those whose patterns were either highly suggestive of a *de novo* ($N=40$, Figure 1a) or were ambiguous ($N=33$, Figure 1b), proband and parent DNAs were examined on custom Agilent SurePrint G3 Human CGH Microarrays on which 50–200 probes were placed to cover each CNV




Figure 1 Histograms of distributions of z-scores. (a) A suggestive *de novo* and (b) an ambiguous *de novo* MeZOD call. Black arrows indicate the position of a parent, and red arrows of a child. The x axis shows the median z-scores for all individuals for a particular copy number variant (CNV) region.

(depending on CNV size). For quality control purposes, we also included probes on all putative *de novos* identified by the first-pass Genotyping Console analysis, but that were subsequently rejected as false positives by the MeZOD method.

To re-call CNVs in the Bulgarian controls, we used the same filtering criteria and accepted only those considered highly suggestive by the MeZOD. Although we did not validate these on Agilent arrays, our calls have a demonstrable low false positive rate ($< 1\%$, Supplementary Section 4). This is much less than the corresponding false positive rate for *de novos* whose rarity confers more unfavourable signal-to-noise characteristics.

Icelandic samples These were genotyped using Illumina bead arrays (HumanHap317, HumanHap370 and HumanHap1M). BeadStudio (Illumina, San Diego,

CA, USA; version 2.0) was used to call genotypes, normalise signal intensity data and establish the log R ratio and B allele frequency at every single-nucleotide polymorphism. Samples passing quality control were examined using PennCNV (10.1101/gr.6861907). Calls required 10 consecutive markers based upon the subset of markers present on all genotyping chips listed above (the HumanHap317 content). All putative *de novo* events were visually inspected using DosageMiner software (developed by deCODE Genetics). CNVs were excluded according to low copy repeat content and frequency as for the Bulgarian sample. This resulted in 59 CNVs, an autosomal *de novo* rate of 2.2%. Given the difference in the platforms, we undertook a number of analyses to confirm that the Icelandic *de novos* are a suitable comparator group for the case *de novos* (see Results and Supplementary Material).

MGS/ISC/UK/Japan. MGS samples were analysed in the same way as the Bulgarian samples including MeZOD. Data for ISC² UK³ and Japanese samples²⁶ were taken from the original publications, and CNVs at loci of interest were manually verified in the available raw data (further information in Supplementary Material).

Gene set analyses

Sets. We collated experimentally defined proteomic data sets corresponding to the structures listed in Table 2. The details of how those gene sets were collated are provided in Supplementary Section 10. We also examined sets based upon the Gene Ontology system (GO sets) in the gene2go file available from the NCBI (National Center for Biotechnology Information) on 28 July 2010 (Supplementary Section 11).

Statistical approaches. A gene was considered 'hit' if a CNV was overlapped according to the NCBI Build 36.3. Full details of mapping are given as Supplementary Section 10.

The impact of biases relating to gene-set analyses of CNVs have been discussed elsewhere.¹⁹ To overcome those biases, we fitted the following logistic regression models to the combined set of case and control (or control *de novo*) CNVs and compared the change in deviance between (1) and (2).

- (1) $\text{logit}(\text{pr}(\text{case})) = \text{CNV size} + \text{Total number of genes hit outside the gene set} + \text{number of genes hit in the gene set}$.
- (2) $\text{logit}(\text{pr}(\text{case})) = \text{CNV size} + \text{Total number of genes hit outside the gene set}$.

Significance was assessed by one-sided test of an excess of genes hit in the gene set by case CNVs. The inclusion of CNV size allows for case *de novo* CNVs being larger than typical CNVs (and thus likely to hit more genes). Inclusion of the total number of genes hit outside the gene set in the regression corrects for case CNVs hitting more genes overall (regardless of function) than control CNVs. Although explicitly adjusted for in the above analysis, to confirm that

the results are not due to the fact that *de novo* CNVs are more likely to hit genes, we also performed an analysis restricted to CNVs that hit genes.

We used the same method to compare the number of genes in gene sets hit by case *de novos* with those hit by (1) 1367 CNVs from the 605 Bulgarian unaffected controls (2) 59 *de novos* found in Icelandic controls and (3) 14 control *de novos* from the unaffected sibs of autism probands.²⁵ The analyses control for different sources of potential bias including array type (the Bulgarian controls) and the possibility that *de novos* have fundamentally different characteristics (other than size that is adjusted for) than control CNVs.

To investigate the impact of using 'control' CNVs, we undertook a random placement analysis comparing the number of *de novo* CNVs hitting each gene set with that found when CNV locations were randomised, importantly ensuring that each random assignment hits at least one gene, and that the probability of a gene being hit was proportional to its length (Supplementary Section 12).

Partitioning the signals in gene sets. Gene sets are not fully independent, for example, some members of the synaptic vesicle set (Table 2) are also members of the postsynaptic density (PSD). To determine which among overlapping sets appeared to be responsible for a gene-set enrichment, we undertook conditional regression analyses as described in Supplementary Section 13.

Meta-analysis of case-controls. For meta-analysis combining cases and controls from multiple studies, we included in the above regression models a "study" term added as an *N*-level factor (where *N*=number of case/control sets being combined). This makes the analysis robust to differences between studies in chip, analytic method and other study-specific factors.

Results

We identified 34 confirmed *de novo* CNVs (Table 1), a rate in all cases of 5.1%. Detailed descriptions of individual *de novo* CNVs are given in Supplementary Section 6 and in the Discussion section. As in an earlier study,²⁴ the *de novo* rate in those with a history of psychosis in a parent was lower (1.6%) than in those without such history (5.5%), although this was not statistically significant. Parents of probands with *de novos* were not older at the time of birth of their children than parents of probands without *de novos*: (27.8 vs 28.7 years, respectively, for fathers and 25.1 vs 25.1 years for mothers). Probands with *de novo* CNVs (Table 1) did not differ from the rest of the probands regarding age at onset (23.9 vs 23.8 years, $P=0.9$) and average school results (4.5 vs 4.7, $P=0.5$), and both sets of probands had similar numbers of children (0.52 vs 0.59, $P=0.6$). In those instances (21) where it was possible to determine the parental origin, more *de novos* occurred in the paternal ($P=14$) than the maternal ($n=7$) genome but this

Table 1 List of *de novo* CNVs found in the study

Cytoband	Location	Type	Size (bp)	Genes	Origin of mutation, F:M SNPs	Diagnosis	Schooling	Children	Age at onset/ age at sampling	Somatic
1q21.1	chr1:144101459–144503409	Del	401 950	16 genes, TAR region	10F:0M	SA	V good, college	2	40/49	Psoriasis
1q43	chr1:235475280–235639644	Del	164 364	<i>RYR2</i>	12F:0M	SZ, par	Good	—	21/33	Patent ductus arteriosus ^b
2q21.2	chr2:133504420–133879778	Del	375 358	<i>NAP5</i>	7F:0M	SZ, par	V good	1	18/25	—
3q13.12	chr3:109330592–110198715	Dupl	868 123	9 genes	11F:0M	SZ, cat	Pass	2	33/48	—
3q29 ^a	chr3:197185548–198825231	Del	1 639 683	21 genes, 3q29 syndrome	56F:0M	SZ, par	Good, college	—	19/45	Congenital heart disease
4q13.3	chr4:70935504–70969553	Del	34 049	<i>HTN1, HTN3</i>	—	SZ, cat	Excellent, college	—	24/33	—
4q21.21	chr4:79944612–80081979	Del	137 367	<i>BMP2K, PAQR3</i>	—	SZ, par	Excellent	1	32/33	—
6q12	chr6:68675955–68761101	Dupl	85 146	—	—	SZ, par	Excellent	—	23/29	Hypertension
7p14.1	chr7:38260614–38307187	Del	46 573	<i>TARP</i>	—	SA	Excellent, university	—	17/24	Asthma
7q11.23	chr7:72390286–76445231	Dupl	4 054 945	38 genes, WBS region	1F: 45M	SZ, dis	V good	—	17/28	—
7q32.1	chr7:127275795–127447967	Del	172 172	<i>C7orf54, SND1</i>	—	SA	V good	—	25/35	—
8p23.2	chr8:4121968–4299810	Del	177 842	<i>CSMD1</i>	0F:23M	SZ, par	Excellent, university	—	17/37	—
8p23.1	chr8:10066862–10155414	Del	88 552	<i>MSRA</i>	—	SZ, par	Pass	—	15/41	—
9p22.3	chr9:16310745–16327782	Del	17 037	—	—	SA	Excellent, university	1	34/37	—
9q31.3	chr9:110859131–111433199	Dupl	574 068	4 genes	—	SZ, ns	Pass	—	9/26	—
9q34.3	chr9:139762152–139797423	Dupl	35 271	<i>EHMT1</i>	—	SZ, ns	V good	2	20/37	Overweight
9q34.3	chr9:139769564–139792102	Del	22 538	<i>EHMT1</i>	—	SZ, dis	Pass	1	24/36	Overweight
11q14.1	chr11:83472750–83842973	Del	370 223	<i>DLG2</i>	0F:M12	SZ, cat	V good, college	—	18/22	—
11q14.1	chr11:84006106–84226064	Del	219 958	<i>DLG2</i>	10F:0M	SZ, par	Pass	2	20/35	—
12q24.13	chr12:111723795–111776045	Del	52 250	<i>RPH3A</i>	—	SZ, par	Good	—	21/33	Patent ductus arteriosus ^b
12q24.33	chr12:130388037–130659530	Dupl	271 493	—	—	SZ, par	Good	—	27/33	—
13q14.11	chr13:40319620–41182276	Del	862 656	8 genes	15F:0M	SZ, par	Good	—	22/33	—
14q13.2	chr14:34464771–34627720	Del	162 949	3 genes	1F:0M	SA, FH+	Excellent	—	16/24	—
15q11.2 ^a	chr15:19548923–20852202	Del	1 303 279	8 genes	0F:16M	SZ, par	Pass	—	32/42	—
15q11.2 ^a	chr15:20224751–20777909	Dupl	553 158	5 genes	0F:10M	SA	Pass	1	20/28	—
15q11.2 ^a	chr15:20224751–20852202	Dupl	627 451	5 genes	0F:8M	SA	Good	—	29/31	—
15q11.2 ^a	chr15:20302446–21038975	Del	736 529	6 genes	19F:0M	SZ, par	V good	1	17/28	—
15q13.1	chr15:26785056–28289366	Dupl	1 504 310	4 genes	0F:2M	SZ, dis	Pass	—	23/43	—
15q13.3 ^a	chr15:28707904–30326817	Del	1 591 596	7 genes	93F:0M	SZ, par	Pass	—	31/38	—
15q13.3 ^a	chr15:28707904–30299500	Del	1 618 913	7 genes	25F:0M	SZ, par	V good	—	32/52	—
16p11.2 ^a	chr16:29488112–30099396	Dupl	611 284	31 genes	21F:0M	SZ, par	Excellent, college	1	35/46	Rheumatoid arthritis
18p11.31	chr18:3515935–4332609	Del	816 674	<i>DLGAP1, FLJ35776</i>	61F:0M	SZ, par	Good	1	18/25	—
20p12.1	chr20:14694326–14863051	Del	168 725	<i>MACROD2</i>	2F:0M	SZ, cat	V good	1	32/37	—
21q21.1	chr21:22698250–22778244	Del	79 994	—	—	SA	Excellent, university	—	29/30	Single febrile convulsion

Abbreviations: CNV, copy number variant; SA, schizoaffective disorder; SNP, single-nucleotide polymorphism; SZ, cat, catatonic schizophrenia; SZ, dis, disorganised schizophrenia; SZ, ns=schizophrenia, not otherwise specified; SZ, par, paranoid schizophrenia; TAR thrombocytopenia absent radius; WBS, Williams–Beuren syndrome.

^aIndicates a known schizophrenia locus.

^bSame patient who has two *de novos*.

Origin of mutation indicates whether the mutation had occurred on the paternal or maternal chromosome. The number of informative SNPs supporting parental origin are given in the order father(F):mother(M). Additional detail is given in Supplementary Section 6. Coordinates in the paper refer to the UCSC (University of California, Santa Cruz) human genome assembly hg18 (National Center for Biotechnology Information (NCBI) build 36). Final school results in Bulgaria are reported as 2 = fail, 3 = pass, 4 = good, 5 = very good, 6 = excellent.

was not statistically significant ($P=0.13$). The non-significant excess of paternal *de novos* was largely attributable to CNVs that were not generated by nonallelic homologous recombination, eight such events being observed on chromosomes of paternal origin compared with two on those that were maternally derived, although this is not significantly different from chance ($P=0.06$).

In order to estimate the *de novo* CNV rate in controls for comparison with cases, we compared the case *de novo* rate with that in controls from two sources, the Icelandic population controls and the unaffected sibs from a recent large study of autism²⁵ (Supplementary Table S3). The *de novo* mutation rate in our cases was higher than in both sets of controls (2.2%, $P=0.00015$ and 1.6%, $P=0.00008$, respectively), both of which had a similar rate ($P=0.28$) despite differences in the density of markers in the control genotyping platforms.

In order to exclude the possibility that the increased *de novo* rate seen in cases reflected the different platforms²⁸ used in our cases and the control studies, we undertook sensitivity analyses. If the elevation in *de novos* in cases is an artefact of greater call sensitivity in the present study, the enrichment we observed should be biased towards smaller CNVs, larger CNVs being called reliably after exclusion of CNVs spanning complex repeat regions (as we have done).²⁸ However, relative enrichment for *de novos* among cases was similar for large *de novos* >500 kb (2.1% vs 0.8%, $P=0.0014$) as it was for small *de novos* <200 kb (2.3% vs 0.9%, $P=0.0035$), and the overall size distribution of case *de novos* was not shifted towards smaller CNVs (Figure 2 and Supplementary Table S3) compared with the control *de novos*. In general, duplications are less easily detected by microarrays than deletions. To exclude the possibility that the excess of *de novos* in cases

reflects a lower sensitivity of the control platforms to detect duplications, we also examined the duplication/deletion ratios in the data sets. These were not significantly different ($P>0.35$ for each sample), although contrary to the hypothesis of a selective loss of sensitivity to detect duplications, both sets of controls actually had a higher proportion of duplications (Icelandic=0.39, Autism controls=0.36) than the cases (0.29). Further details on the size distribution of the *de novo* CNV are given in Supplementary Section 8, and of the full sensitivity analyses in Supplementary Section 1. Finally, we note that the control rates were similar to those in our experimental group with an affected parent (who according to an earlier work²⁴ do not have elevated rates of *de novo* mutation), suggesting that technical variation between our own and other studies does not make a major impact on our conclusions.

Analysis of *de novo* loci in case-control studies

We examined the fully independent case-control data sets for rare CNVs at the novel loci affected by case *de novos*, including CNVs only of the same class that had been observed to have occurred as *de novos* (that is, deletions, duplications or both where relevant) (Supplementary Section 7) that intersected at least one exon of a gene (details in Supplementary Table S1). Even after an extremely conservative approach of excluding all CNVs (deletions and duplications) at known schizophrenia loci represented among our *de novos* (3q29, 15q11.2, 15q13.3 and 16p11.2), we found rates of 0.4% (32/7907) in cases and 0.21% (22/10585) in controls, a twofold enrichment (Fisher one-tailed $P=0.012$). We did not obtain evidence for association to individual CNV loci at a level that would survive correction for multiple testing ($N=19$ excluding the known schizophrenia loci, giving a Bonferroni corrected threshold of $P=0.0025$). However, nominally significant associations (P uncorrected <0.05) were observed for deletions at *DLG2* ($P=0.02$) and *MSRA* ($P=0.03$), whereas the *EHMT1* locus just failed to reach this uncorrected threshold ($P=0.055$). Of interest, although not even nominally significant, we also observed an excess of CNVs in cases at two other loci known to be implicated in nonpsychiatric genomic disorders: deletions of the TAR (thrombocytopenia absent radius) region ($P=0.11$) and duplications of the WBS (Williams-Beuren syndrome) region ($P=0.11$).

Gene-set analyses

We initially undertook gene-set analyses based upon proteomics-based annotations (Table 2 and Supplementary Section 11). To avoid multiple testing involved in subgroup analysis, we present the findings for the full sample of *de novos*, although we note that exclusion of the single *de novo* in a proband with a family history of psychosis in a parent made essentially no difference to the results. Compared with Bulgarian control CNVs, we found a highly




Figure 2 Size of copy number variants (CNVs). Kaplan-Meier survival graph for the size of *de novo* CNVs in cases, Icelandic controls, Bulgarian controls and unaffected siblings of autism probands.²⁵

Table 2 Enrichment of gene sets for *de novo* CNV hits in comparison with control CNVs

Gene set	N genes	N genes hit by CNVs P-value				Genes hit by SCZ de novos
		SCZ de novo (34)	Bulgarian control (1367)	Icelandic control de novo (59)	Autism control de novo (14)	
PSD	664	19	49 (1.72×10^{-6})	13 (0.045)	4 (0.11)	DLG1, DLG2, DLGAP1, RYR2, SND1, STX1A, MDH2, HSPB1, YWHAG, RPH3A, CYFIP1, TJP1, ALDOA, TACK2, MAPK3
ARC complex	25	8	7 (3.78×10^{-8})	1 (2.51×10^{-4})	0 (0.0049)	DLG1, DLG2, DLGAP1, CYFIP1
NMDAR complex	59	8	6 (4.24×10^{-6})	2 (0.0061)	0 (0.01)	DLG1, DLG2, DLGAP1, STX1A, YWHAG, TJP1, MAPK3
PSD-95 complex	58	4	3 (1.17×10^{-5})	1 (0.017)	0 (0.033)	DLG1, DLG2, DLGAP1
mGluR5 complex	37	3	4 (0.026)	2 (0.45)	0 (0.15)	YWHAG, RPH3A, ALDOA
Presynapse	426	8	25 (0.033)	8 (0.32)	2 (0.28)	STX1A, RPH3A, CYFIP1, ALDOA, MDH2
Synaptic vesicle	333	7	20 (0.014)	8 (0.39)	2 (0.31)	STX1A, RPH3A, CYFIP1, ALDOA
Active zone	176	2	6 (0.29)	3 (0.91)	0 (0.26)	ALDOA, MDH2
Nucleus	160	5	10 (0.0024)	2 (0.026)	0 (0.018)	CYFIP1, TJP1
Mitochondrion	189	3	9 (0.41)	1 (0.11)	0 (0.093)	MDH2, BDH1, KIAA0564
Cytoplasm	263	4	11 (0.68)	3 (0.55)	0 (0.15)	EIF4H, YWHAG, MSRA, MVP
Endoplasmic reticulum	94	1	3 (0.75)	0 (0.18)	0 (0.31)	POR
Endoplasmic reticulum/ Golgi-derived vesicles	94	0	0	0	0	
Recycling endosomes	65	0	2 (0.83)	0	0	
Early endosomes	17	0	1 (0.82)	0	0	
Golgi	31	0	1 (0.82)	0	0	
Plasma membrane	50	0	2 (0.61)	0	0	

Abbreviations: ARC, activity-regulated cytoskeleton-associated protein; CNV, copy number variant; NMDAR, N-methyl-D-aspartate receptor; PSD, postsynaptic density; SCZ, schizophrenia.

Gene sets were tested for enrichment in 34 schizophrenia ('SCZ') *de novo* CNVs compared with 1367 CNVs found in 605 Bulgarian controls ('controls'), 59 *de novo* CNVs found in 2623 unaffected individuals from the Icelandic population ('Icelandic control de novo') and 14 *de novo* CNVs found in unaffected siblings of autism proband from the study by Sanders et al.²⁵ ('Autism control de novo'). 'N genes' refers to number of genes in the set. P-values are presented underneath the number of genes hit and correspond to one-tailed tests of an excess of gene hits in case CNVs. P-values in bold are significant. 'N genes hit by CNVs' refers to the number of times any gene in the set is hit by a CNV. The unique genes hit in each set are given in the final column. Genes in bold are present in multiple subcellular components.

significant excess of PSD genes within case *de novos* ($P=1.72 \times 10^{-6}$; Table 2). As expected, the results where the analysis was restricted to CNVs hitting genes were similar to those of the primary analysis (data not shown).

Significant enrichments were also observed in presynaptic vesicle and nuclear gene sets, but not after conditioning on the PSD ($P_{\min}=0.66$), whereas the PSD gene set remained significantly enriched for hits after conditioning on the other sets individually ($P_{\max}=5.20 \times 10^{-3}$) or combined ($P=0.016$) (Supplementary Section 13). The most parsimonious interpretation is that our findings specifically implicate the PSD, although we cannot exclude the possibility of effects across multiple functional sets.

To explore our findings in the context of a less restricted set of classifications, we performed enrichment analyses using the GO annotation. Of all categories, 'the synapse' (GO: 45202) was by two orders of magnitude the most significantly enriched ($P=9.6 \times 10^{-9}$) (Supplementary Section 11 and Supplementary Table S4) but most of this signal was attributable to the PSD gene set ($P=0.049$ after removing PSD genes, Supplementary Table S5). Only one subcategory of 'the synapse' GO: 45202

was enriched after PSD genes were removed: GO: 30672 'synaptic vesicle membrane' ($P=0.036$, Supplementary Table S5).

Aiming to localise more specifically the source of the PSD gene-set enrichment, we tested gene sets encoding PSD components (Table 2 and Figure 3). Activity-regulated cytoskeleton-associated protein (ARC; $P=3.78 \times 10^{-8}$), N-methyl-D-aspartate receptor (NMDAR; $P=4.24 \times 10^{-6}$) and PSD-95 complex ($P=1.17 \times 10^{-5}$) genes were highly significantly enriched among the *de novos*. However, conditional analyses revealed that the relatively small ARC and NMDAR sets explained both the PSD (conditional $P_{\text{PSD}}=0.231$) and PSD-95 (conditional $P_{\text{PSD-95}}=0.603$) enrichments but that the enrichments in ARC and NMDAR were partially independent of each other (conditional $P=2.17 \times 10^{-4}$ and $P=0.019$, respectively) (Supplementary Section 13). ARC and NMDAR sets also explained most of the enrichment for *de novos* in 'the synapse', this GO category being only marginally enriched ($P=0.017$) after those genes were removed (Supplementary Section 11 and Supplementary Table S5). After removal of members of ARC and NMDAR sets, none of the subcategories comprising the synapse was significantly enriched




Figure 3 Disruption of postsynaptic signalling within activity-regulated cytoskeleton-associated protein (ARC) and *N*-methyl-D-aspartate receptor (NMDAR) complexes by copy number variants (CNVs). ARC and NMDAR bind to diverse structural and signalling molecules forming multi-protein complexes. Functional pathways encoded by these complexes are disrupted by *de novo* CNVs at multiple levels, as indicated by the purple asterisks (number of asterisks = number of *de novos* overlapping a gene or gene family). Calcium influx via the NMDAR, modulated by calcium release from internal stores (RYR2), drives downstream pathways whose association with the receptor is mediated by scaffold proteins (*DLG1*, *DLG2*, *DLGAP1*). Multiple pathways converge on ERK kinases (extracellular signal-regulated kinases), a focal point in the regulation of ARC transcription, dendritic localisation and local translation.⁴⁷ ARC mRNA is transported to sites of synaptic activity in complexes containing *CYFIP1*, dissociation of which is required for ARC translation.⁴⁹ *CYFIP1* also regulates translation of *CAMKII*,⁴⁹ a key component of NMDAR complexes. Although not identified in this study, deletions of synaptic adhesion protein *NRXN1* (blue asterisk) have previously been found in schizophrenia.²⁹ CNVs disrupting genes within these same functional pathways have also been identified in autism³⁰ (black asterisks).

except for ‘synaptic vesicle membrane’ ($P=4.22 \times 10^{-4}$). These findings suggest enrichments in the PSD, and the great majority of that in the synapse GO gene set, is because of the enrichments in

ARC and NMDAR, but that there is residual enrichment elsewhere in the synapse that is captured by ‘synaptic vesicle membrane’ genes (GO: 30672).

To exclude unknown possible sources of confounding arising from the use of control CNVs, we also compared gene sets hit by *de novo* CNVs from cases with those hit in random assignments of gene-hitting CNVs of the same size, ensuring the probability of a gene being hit was proportional to its size. Again, we observed significant enrichment of PSD genes ($P=0.0024$), and a highly significant enrichment of the ARC (2.21×10^{-8}) and NMDAR (2.95×10^{-4}) complexes (Supplementary Section 12).

To exclude the possibility that our results reflect general properties of *de novo* CNVs, we compared case *de novo* CNVs with *de novo* CNVs identified in the control individuals from Iceland and from the Autism study by Sanders *et al.*²⁵ Despite fewer control CNVs in these samples ($N=59$ and $N=14$), and therefore reduced power, the findings were consistent with our primary analysis in showing significant enrichment of ARC and NMDAR (Table 2) as were those of sensitivity analysis restricted to very large CNVs (>500 kb) (ARC $P=1.27 \times 10^{-4}$; NMDAR $P=1.72 \times 10^{-2}$).

Finally, we examined the ARC/NMDAR gene sets in the large case–control data sets. In this completely independent analysis, case CNVs were significantly enriched for members of the NMDAR ($P=0.0015$) but not ARC complexes ($P=0.14$). We note that in the *de novo* analysis, much of the additional signal for the ARC complex (over and above that of the NMDAR) comes from CNVs at 15q11.2 that span *CYFIP1*. Although there is strong published evidence for deletions at this locus being relevant to schizophrenia,^{3,7} this locus was not significantly enriched in the MGS study,⁴ and was excluded by the filtering criteria adopted by the ISC,² the two studies that combined comprise a large proportion of the case–control data set we use in this study.

Discussion

Aiming to identify novel candidate CNV loci for schizophrenia, and to illuminate aspects of the pathophysiology of the disorder through gene-set enrichment analyses, we have conducted the largest analysis of *de novo* CNVs in schizophrenia to date. Although not every observed case *de novo* CNV is likely to be pathogenic, the hypothesis that a substantial proportion of them are likely to be so is supported by several observations. First, eight of the *de novos* occurred at already known schizophrenia CNV loci (Table 1, marked with footnote ‘a’). Second, even after conservatively excluding those known loci, CNVs at the loci affected by case *de novos* occurred twice as frequently in cases in a meta-analysis of the largest available case–control CNV data sets. This elevation is much higher than the overall increase in CNV burden in cases in the large published studies.^{2,4} Third, in the trios sample, the rate of *de novo* CNVs

was more than twice that observed in other control samples (Supplementary Table S3), suggesting that at least 50% of the case *de novos* are relevant to the pathophysiology of schizophrenia.

Our estimate of the *de novo* rate is lower than initial reports in autism²³ and schizophrenia²⁴ but is comparable with more recent estimates in autism.^{25,29,30} *Post hoc* evaluation suggests it is unlikely that our filtering steps excluded large numbers of true *de novo* CNVs within our target size range. Of the 34 Agilent-validated *de novos*, 91% ($N=31$) had been rated (using MeZOD) as highly suggestive, whereas only 9% ($N=3$) had been called as ambiguous. Conversely, none of 33 putative *de novos* called by the Genotyping Console that were rejected by MeZOD were confirmed by Agilent.

It is notable that two previously documented schizophrenia loci, at 15q11.2 and 15q13.3, were each found more than once as *de novos* (Table 1). Two other loci were represented by two *de novo* CNVs each: *EHMT1* (encoding Eu-HMTase1), a histone H3 Lys 9 (H3-K9) methyltransferase, and *DLG2* (encoding discs, large homologue 2). Moreover, one *de novo* spanned each of the related genes *DLG1* (whose orthologue in *Drosophila* is also *dlg1*) and *DLGAP1* (encoding discs large associated protein 1).

At *EHMT1* we observed a total of two *de novos*, three additional exonic CNVs in cases and one in a control. *EHMT1* haploinsufficiency has been implicated as the cause of the 9q subtelomeric deletion syndrome (9qSTDS) characterised by moderate-to-severe mental retardation, childhood hypotonia and facial dysmorphisms, as well as a high prevalence of psychiatric symptoms in adulthood.³¹ A recent study has also reported strong evidence that deletions at *EHMT1* are highly penetrant for phenotypes comprising developmental delay and a range of congenital anomalies.³² With this additional evidence for the involvement of this gene in neurodevelopmental phenotypes, our data point to *EHMT1* as a schizophrenia susceptibility gene. Intriguingly, in *Drosophila*, *ehmt* coordinates epigenetic changes important in regulating cognition.³³ Our findings at this locus thus suggest a role for epigenetic mechanisms in at least some cases of schizophrenia, and potentially point the way to novel therapeutic opportunities as the developmental effects of *ehmt* mutation on cognition are reversible.³¹

The DLG (discs large) family of membrane-associated guanylate kinases (MAGUKs), which were hit by multiple case *de novo* CNVs, are components of postsynaptic signalling complexes that are embedded within the larger group of over 1000 proteins that make up the PSD.³⁴ They are associated with NMDA receptors and are highly concentrated in synapses. Remarkably, the orthologue of *DLG2* in *Drosophila* (*dlg1*) is directly regulated by the orthologue of *EHMT1* (*emht* also known as G9a).³³ CNVs spanning *DLG1* and *DLG2* have been reported before in schizophrenia^{4,6,17} whereas other members of the family (*DLG3* and *DLGAP2*) have been implicated in

mental retardation³⁵ and autism.^{30,36} Together with our observation of multiple *de novos* spanning members of this family, and the nominally significant association of exonic CNVs at *DLG2* in the case-control analysis, the findings strongly suggest that the CNVs we report in *DLG*-related genes are likely to be of pathogenic relevance to schizophrenia.

Although not strongly implicated by our study, a number of singleton *de novo* CNVs are also of note as they are at loci known to be associated with rare genomic disorders. The first is a deletion at 1q21.1 reported in TAR syndrome³⁷ (which does not overlap the known 1q21.1 schizophrenia locus^{2,7}). We found the TAR region deleted in three more cases and only one control from the extended case-control samples. Again, deletions at this locus have very recently been strongly implicated in developmental delay.³² Another region is a duplication at the locus causing the 7q11.23 microduplication syndrome (which is deleted in Williams-Beuren Syndrome), the prominent features of which include autism and developmental delay.³⁸ Duplications at the WBS region were found in three more cases and one control. Although this excess is not statistically significant ($P=0.11$, uncorrected), given duplications at this locus have also recently been identified increasing susceptibility for autism²⁵ and developmental delay,³² it seems likely that the observations in the present study point to the involvement of this locus in schizophrenia as well. Further details about each of these loci are provided in Supplementary Section 6.

Given that our data suggest *de novo* CNVs are highly enriched for pathogenic loci, we sought evidence for convergence of *de novo* events onto specific biological pathways using a hypothesis-led, systems biology approach. Many of the CNVs robustly implicated in schizophrenia are also implicated in neurodevelopmental disorders in which cognitive impairment is common.³⁹⁻⁴¹ Moreover, as discussed in the Introduction, it has been hypothesised that schizophrenia CNVs are enriched for genes encoding proteins associated with synaptic function. Our findings of apparent convergence of *de novo* CNVs onto genes encoding MAGUK proteins broadly support this synaptic hypothesis and suggested that more refined examination of synaptic genes is warranted.

Cognitive deficits are increasingly recognised as core features of schizophrenia, and it has long been known that antagonism of NMDA receptors at glutamatergic synapses can induce a schizophrenia-like psychosis that includes some of those deficits.⁴² This has led to a glutamate hypofunction hypothesis of schizophrenia. Glutamate receptors form multi-protein complexes with large sets of scaffold and signalling proteins including MAGUKs⁴³ that are embedded in the PSD. It is clear that disruption of a number of synaptic proteins linked to glutamate receptor signalling alters cognitive function in rodents.⁴⁴ The composition of the PSD has recently been identified in humans by some of the present authors,³⁴ affording us an unprecedented opportunity

to investigate the role of this complex in schizophrenia. Specifically, we tested the hypothesis that *de novo* CNVs in cases are enriched for genes encoding members of this complex.

We first compared the case *de novos* with a set of control CNVs drawn from the same population as the trios. Although those CNVs must have originally occurred as *de novo* mutations, predominantly transmitted CNVs clearly have different characteristics from the case *de novos*, most obviously size. Although our set-based analyses allow for size differences, to ensure our findings were robust to the control data set, we also compared gene sets hit by case *de novo* CNVs with those hit in random assignments of gene-hitting CNVs of the same size and obtained very similar gene-set enrichments. Finally, in order to exclude the possibility that our findings reflected general properties of *de novo* CNVs, we compared case *de novo* CNVs to two sets of control *de novos*, one drawn from the Icelandic population and the other from a much smaller sample of unaffected sibs of people with autism. Despite the wide disparities in the sources of the control CNVs, and the potential for different sources of bias, the results converge in pointing to the involvement of the synapse, the PSD, and more specifically, ARC and NMDAR complexes. Finally, and fully independent of those analyses, we show a significant enrichment for genes in the NMDAR complex in a meta-analysis of case-control data sets. We think it likely that the weaker finding for the NMDAR complex in the large case-control study compared with the relatively small *de novo* study, and the absence of association to ARC in the former, reflects the much lower power of the case-control design as a result of poorer enrichment for pathogenic CNVs.

This study adds to an accumulating body of evidence from human and animal genetic studies implicating disruption of synaptic processes in schizophrenia.⁴⁵ By identifying an unprecedentedly large number of *de novo* CNVs in schizophrenia and demonstrating that these are likely to be highly enriched for pathogenic events, we have added substantially to the evidence implicating synaptic processes in schizophrenia. As well as implicating a set of functionally related synaptic proteins (*EHMT1*, *DLG2*, *DLG1* and *DLGAP1*) we have identified a sufficient number of schizophrenia-enriched loci to identify potential points on convergence on specific synaptic complexes. Using gene sets that have been systematically annotated from individual, high-quality proteomic data sets and multiple analytic approaches carefully controlled for biases, we not only provide strong evidence for the importance of synaptic proteins, but also provide novel convergent support for the involvement of NMDAR, and to a lesser extent ARC protein, complexes in the aetiology and pathogenesis of the disorder, both of which are involved in NMDA signal transduction. NMDA receptor signalling regulates induction of multiple forms of synaptic plasticity,⁴⁶ with local synthesis of

ARC central to synaptic remodelling and the long-term maintenance of synaptic changes.⁴⁷ Our finding that 12 out of the 34 case *de novos* impact on ARC and/or NMDAR complexes, supported by robust statistical analyses, suggest that disruption of NMDA signalling plays a key role in at least some cases of schizophrenia. As noted above, our findings do not exclude a role for mutations in other post- or pre-synaptic complexes, and given the close functional relationship between different synaptic components, we might expect pathology at a number of different points to play a role. Indeed, the robust association between *NRXN1* deletions and schizophrenia⁴⁸ points to presynaptic disruption in some cases, a hypothesis further supported by enrichment for case *de novos* in the GO category 'synaptic vesicle membrane' after adjustment for ARC and NMDAR. Our findings delineate a circumscribed set of largely postsynaptic proteins and functions that warrant further functional analysis in model systems.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

We acknowledge the families who participated in the study. Funding for recruitment was provided by the Janssen Research Foundation. Genotyping was funded by multiple grants to the Stanley Center for Psychiatric Research at the Broad Institute from the Stanley Medical Research Institute, The Merck Genome Research Foundation and the Herman Foundation. Work at Cardiff University was funded by Medical Research Council (MRC) Programme (Ref G0800509) and Centre Grants, the National Institutes of Mental Health (USA) (CONTE: 2 P50 MH066392-05A1) and a grant from the EU (EU-GEI). Genotyping and CNV analysis in the Icelandic trios by deCODE Genetics was funded in part by EU grants: HEALTH-2007-2.2.1-10-223423 (Project PsychCNV), PIAG-GA-2008-218251 (Project PsychGene) and IMI-JU-NewMeds. SGNG, ÅB, EF, LNVL, JC, NHK and MOC were supported by the Genes to Cognition Program funded by the Wellcome Trust, MRC Project (Ref G06706B), EU grants: (Project GENCODYS Nr 241995, Project EUROSPIN No. 242498 and Project SYNSYS No. 242167). ÅB is supported by EMBO and the European Commission. We acknowledge Edward Scolnick for helpful discussions.

The following psychiatrists in Bulgaria recruited families for the project:

District Hospital Blagoevgrad: Nikolay Ianakiev, Radoi Milev, Valentina Kovachka.

University Hospital Sofia: Vihra Milanova, Georgy Koichev, Stefan Krastev, Georgi Onchev, Elitza Djatova, Tsveteslava Galabova, Desislava Ivanova, Ivan Gerdjikov, Emil Kaludiev, Christian Kostov, Ivanka Krastnikova, Irina Lazarova, Nedialko Mihailov, Maria Nikolova, Iliana Pristavova, Kalina

Shoilekova, Anton Slavchev, Vladimir Sotirov, Svetla Stambolova, Miroslava Stamenova, Vessela Stoianova, Milena Strashimirova, Snezhina Tacheva, Todor Todorov, Rositza Vladimirova.

Plovdiv University Hospital: Marin Roglev, Inko Kehaiov, Nadezhda Poryazova, Rayna Tsvetkova, Petia Blagoeva, Veselina Vlahova.

Radnevo Psychiatric Hospital: Todor Tolev, Kalinka Drebova, Penka Grozeva, Ivan Ivanov, Mariya Nikolova, Maya Pashova, Radka Patricheva, Minka Sokolovska, Antoniya Terzieva, Donka Terzieva, Vania Tesheva, Iliana Topcheva, Vladimir Trynov.

Psychiatric Hospital, Russe: Temenujka Mateva, Biliana Mechkunova, Plamen Panayotov, Rositsa Vacheva.

Psychiatric Dispensary, Sofia: Lubomir Jivkov, Svetlinka Koleva, Kalina Georgieva, Tatiana Kanova, Anna Maikova, Krasimira Marcheva, Vesselin Sekoulov, Diana Shkodrova, Vesselina Slavcheva, Tenko Tenev, Lora Tsoneva.

DNA handling and extraction was performed at the Department of Medical Genetics, University Hospital 'Maichin Dom', Sofia (Head of Department Professor Draga Toncheva): Lyudmila Georgieva, Albena Dimitrova and Irina Zaharieva.

Author Contributions

GK, MJO, MCO'D, PS and SP designed the study. GK, MJO and MCO'D drafted the primary manuscript along with AJP, PH and SG. The primary genotyping analysis with Affymetrix arrays was organised and coordinated by SP, PS, JM and KC. MI, GK, DR, SP, MF, DI and RW analysed the raw intensity data. CNV analysis was performed by GK, DI, MF, ER and DR. MF and GK designed the Agilent custom arrays. DG, MI, LG and GK performed the Agilent validation experiments. HS, KS, PIO and YB were responsible for analysis of Icelandic trios. Synapse proteomic data sets were prepared by LNVL, AB, EF, MOC, JC and SGNG. AJP and SGNG identified the curated sets of genes for pathway analyses. PH and AJP analysed the involvement of gene sets in *de novo* CNVs. SP undertook an independent parallel analysis. GK and MJO planned and organised the recruitment of families, which was coordinated by GK, IN and DT. DI wrote the scripts used for *de novo* analysis, including the z-score method. All authors discussed the results, their interpretation and contributed to the final manuscript.

References

- Owen MJ, Craddock N, O'Donovan MC. Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. *Arch Gen Psychiatry* 2010; **67**: 667–673.
- International Schizophrenia Consortium (ISC). Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature* 2008; **455**: 237–241.
- Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P *et al*. Support for the involvement of large CNVs in the pathogenesis of schizophrenia. *Hum Mol Genet* 2009; **18**: 1497–1503.

- Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J *et al*. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. *Am J Psychiatry* 2011; **168**: 302–316.
- Moreno-De-Luca D, Mulle JG, Kaminsky EB, Sanders SJ, Myers SM, Adam MP *et al*. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. *Am J Hum Genet* 2010; **87**: 618–630.
- Mulle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC *et al*. Microdeletions of 3q29 confer high risk for schizophrenia. *Am J Hum Genet* 2010; **87**: 229–236.
- Stefansson H, Rujescu D, Cichon S, Pietilainen OPH, Ingason A, Steinberg S *et al*. Large recurrent microdeletions associated with schizophrenia. *Nature* 2008; **455**: 232–236.
- Vacic V, McCarthy S, Malhotra D, Murray F, Chou H-H, Peoples A *et al*. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. *Nature* 2011; **471**: 499–503.
- Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD *et al*. Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. *Am J Psychiatry* 2011; **168**: 408–417.
- Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietilainen OPH *et al*. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. *Mol Psychiatry* 2011; **16**: 17–25.
- Kirov G, Rujescu D, Ingason A, Collier DA, O'Donovan MC, Owen MJ. Neurexin 1 (NRXN1) deletions in schizophrenia. *Schizophr Bull* 2009; **35**: 851–854.
- McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S *et al*. Microduplications of 16p11.2 are associated with schizophrenia. *Nat Genet* 2009; **41**: 1223–1227.
- Sebat J, Levy DL, McCarthy SE. Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. *Trends Genet* 2009; **25**: 528–535.
- Grozeva D, Kirov G, Ivanov D, Jones IR, Jones L, Green EK *et al*. Rare copy number variants: a point of rarity in genetic risk for bipolar disorder and schizophrenia. *Arch Gen Psychiatry* 2010; **67**: 318–327.
- Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M *et al*. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. *Hum Mol Genet* 2008; **17**: 458–465.
- Tam GWC, Redon R, Carter NP, Grant SGN. The role of DNA copy number variation in schizophrenia. *Biol Psychiatry* 2009; **66**: 1005–1012.
- Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM *et al*. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science* 2008; **320**: 539–543.
- Glessner JT, Reilly MP, Kim CE, Takahashi N, Albano A, Hou C *et al*. Strong synaptic transmission impact by copy number variations in schizophrenia. *Proc Natl Acad Sci USA* 2010; **107**: 10584–10589.
- Raychaudhuri S, Korn JM, McCarroll SA, Consortium TIS, Altshuler D, Sklar P *et al*. Accurately assessing the risk of schizophrenia conferred by rare copy-number variation affecting genes with brain function. *PLoS Genet* 2010; **6**: pii: e1001097.
- Bundy H, Stahl D, MacCabe JH. A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives. *Acta Psychiatr Scand* 2010; **123**: 98–106.
- Laursen TM, Munk-Olsen T. Reproductive patterns in psychotic patients. *Schizophr Res* 2010; **121**: 234–240.
- Rees E, Moskvina V, Owen MJ, O'Donovan MC, Kirov G. *De novo* rates and selection of schizophrenia-associated copy number variants. *Biol Psychiatry*; advance online publication, 18 August 2011 [e-pub ahead of print].
- Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T *et al*. Strong association of *de novo* copy number mutations with autism. *Science* 2007; **316**: 445–449.
- Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. Strong association of *de novo* copy number mutations with sporadic schizophrenia. *Nat Genet* 2008; **40**: 880–885.
- Sanders Stephan J, Ercan-Sencicek AG, Hus V, Luo R, Murtha Michael T, Moreno-De-Luca D *et al*. Multiple recurrent *de novo* CNVs, including duplications of the 7q11.23 Williams

- syndrome region, are strongly associated with autism. *Neuron* 2011; **70**: 863–885.
- 26 Ikeda M, Aleksic B, Kirov G, Kinoshita Y, Yamanouchi Y, Kitajima T *et al*. Copy number variation in schizophrenia in the Japanese population. *Biol Psychiatry* 2010; **67**: 283–286.
 - 27 Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SFA *et al*. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res* 2007; **17**: 1665–1674.
 - 28 Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, Fitzgerald T *et al*. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. *Nat Biotech* 2011; **29**: 512–520.
 - 29 Rujescu D, Ingason A, Cichon S, Pietiläinen OP, Barnes MR, Toulopoulou T *et al*. Disruption of the neurexin 1 gene is associated with schizophrenia. *Hum Mol Genet* 2009; **18**: 988–996.
 - 30 Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R *et al*. Functional impact of global rare copy number variation in autism spectrum disorders. *Nature* 2010; **466**: 368–372.
 - 31 Kleefstra T, van Zelt-Stams WA, Nillesen WM, Cormier-Daire V, Houge G, Foulds N *et al*. Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. *J Med Genet* 2009; **46**: 598–606.
 - 32 Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C *et al*. A copy number variation morbidity map of developmental delay. *Nat Genet* 2011; **43**: 838–846.
 - 33 Kramer JM, Kochinke K, Oortveld MAW, Marks H, Kramer D, de Jong EK *et al*. Epigenetic regulation of learning and memory by *Drosophila* EHMT/G9a. *PLoS Biol* 2011; **9**: e1000569.
 - 34 Bayés A, van de Lagemaat LN, Collins MO, Croning MDR, Whittle IR, Choudhary JS *et al*. Characterization of the proteome, diseases and evolution of the human postsynaptic density. *Nat Neurosci* 2011; **14**: 19–21.
 - 35 Tarpey P, Parnau J, Blow M, Woffendin H, Bignell G, Cox C *et al*. Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation. *Am J Hum Genet* 2004; **75**: 318–324.
 - 36 Guilmatre A, Dubourg C, Mosca A-L, Legallic S, Goldenberg A, Drouin-Garraud V *et al*. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. *Arch Gen Psychiatry* 2009; **66**: 947–956.
 - 37 Klopocki E, Schulze H, Strau G, Ott C-E, Hall J, Trotier F *et al*. Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome. *Am J Hum Genet* 2007; **80**: 232–240.
 - 38 Van der Aa N, Rooms L, Vandeweyer G, van den Ende J, Reyniers E, Fichera M *et al*. Fourteen new cases contribute to the characterization of the 7q11.23 microduplication syndrome. *Eur J Med Genet* 2009; **52**: 94–100.
 - 39 McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S *et al*. Microduplications of 16p11.2 are associated with schizophrenia. *Nat Genet* 2009; **41**: 1223–1227.
 - 40 Sebat J, Levy DL, McCarthy SE. Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. *Trends Genet* 2009; **25**: 528–535.
 - 41 Williams NM, Zaharieva I, Martin A, Langley K, Mantripragada K, Fossdal R *et al*. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. *Lancet* 2010; **376**: 1401–1408.
 - 42 Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. *Pharmacopsychiatry* 1998; **31**(S 2): 104–109.
 - 43 Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SGN. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. *Nat Neurosci* 2000; **3**: 661–669.
 - 44 Grant SG, Marshall MC, Page KL, Cumiskey MA, Armstrong JD. Synapse proteomics of multiprotein complexes: en route from genes to nervous system diseases. *Hum Mol Genet* 2005; **14**: R225–R234.
 - 45 Mitchell KJ. The genetics of neurodevelopmental disease. *Cur Opin Neurobiol* 2011; **21**: 197–203.
 - 46 Malenka RC, Nicoll RA. NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. *Trends Neurosci* 1993; **16**: 521–527.
 - 47 Bramham C, Alme M, Bittins M, Kuipers S, Nair R, Pai B *et al*. The Arc of synaptic memory. *Exp Brain Res* 2010; **200**: 125–140.
 - 48 Kirov G. The role of copy number variation in schizophrenia. *Exp Rev Neurotherapeutics* 2010; **10**: 25–32.
 - 49 Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S *et al*. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. *Cell* 2008; **134**: 1042–1054.



This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/3.0/>

Supplementary Information accompanies the paper on the Molecular Psychiatry website (<http://www.nature.com/mp>)